Stocks Health care USNA
NYSE · Health careUsana Health Sciences Inc (USNA)
Usana Health Sciences Inc brought in $913.4M of revenue over the twelve months to July 4, 2026, up 1.6% from a year earlier. It posted a net loss of $22.2M. Operating cash flow minus capital spending left $8.5M of free cash flow in fiscal 2025. At July 4, 2026 it held $168.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Usana Health Sciences Inc
- Net worth
- Usana Health Sciences Inc has a market value (market cap) of $255.9M at the latest share price, and shareholders' equity of $526.3M on its balance sheet at July 4, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $925.3M (+8.3% year on year), with net income of $10.8M. Over the 12 months to July 4, 2026: revenue $913.4M, net loss $22.2M.
- Cash flow
- In fiscal 2025 operations brought in $22.3M of cash; after $13.8M of capital spending, free cash flow was $8.5M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to July 4, 2026. Open on SEC EDGAR
- Next earnings report
- Usana Health Sciences Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Usana Health Sciences Inc does
Usana Health Sciences Inc is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NYSE under the ticker USNA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $925.3M | $10.8M | $0.58 | $8.5M |
| 2023 | $854.5M | $42M | $2.19 | $50.9M |
| 2023 | $921M | $63.8M | $3.30 | $56.1M |
| 2022 | $998.6M | $69.4M | $3.59 | $93.5M |
| 2022 | $1.2B | $116.5M | $5.73 | $108.5M |
| 2020 | $1.1B | $124.7M | $5.86 | $145.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where USNA ranks in Health care
Latest SEC filings
What Usana Health Sciences Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- October 5, 2026Material agreement8-KUSANA Health Sciences amended its credit agreement to modify financial covenants and permit the sale of real estate in Australia.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to July 4, 2026Revenue fell 5.3% to $223.3M versus the same quarter last year; diluted EPS -$1.16 versus $0.52.
- August 4, 2026
- June 15, 2026
- May 20, 2026
- May 12, 2026Quarterly report 10-Q · period to April 4, 2026Revenue was flat at $250.2M versus the same quarter last year; diluted EPS $0.41 versus $0.49.
- May 5, 2026
- April 7, 2026
What is USNA worth? A DCF from its reported cash flow
Insider trades
What the people running Usana Health Sciences Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 10 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 22, 2026 | Fuller Gilbert ADirector | Exercised options | 1,632 | - |
| October 22, 2026 | Wood Timothy EDirector | Exercised options | 1,632 | - |
| October 22, 2026 | Wood Timothy EDirector | Shares withheld for tax | 408 | $5.9K |
| October 22, 2026 | Winssinger Frederic JDirector | Exercised options | 1,632 | - |
| October 22, 2026 | Nixon J ScottDirector | Exercised options | 1,632 | - |
| October 22, 2026 | Pelosi PeggieDirector | Exercised options | 1,632 | - |
| October 22, 2026 | Pelosi PeggieDirector | Shares withheld for tax | 935 | $13.6K |
| October 22, 2026 | Fleming John TurmanDirector | Exercised options | 1,632 | - |
Who owns USNA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Gull Global Limited13D, may seek influence with 1 related filers | 40.1% | March 30, 2026 |
| Pzena Investment Management LLC13G, passive | 6.6% | October 14, 2025 |
| Renaissance Technologies LLC13G, passive with 1 related filers | 5.19% | August 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 138 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 1,620,148 | +810,074 |
| BlackRock, Inc. | 1,554,189 | +363,773 |
| Pzena Investment Management LLC | 1,205,587 | +96,654 |
| Renaissance Technologies LLC | 958,520 | -59,110 |
| Dimensional Fund Advisors LP | 837,426 | +3,203 |
| Vanguard Capital Management LLC | 487,370 | +8,327 |
| Creative Planning | 417,971 | +224,823 |
| Aqr Capital Management LLC | 408,086 | +111,666 |
| Vanguard Portfolio Management LLC | 363,377 | +25,103 |
| Geode Capital Management, LLC | 283,165 | +18,731 |
| Charles Schwab Investment Management Inc | 272,208 | -60,904 |
| State Street Corp | 261,240 | +13,205 |
| Nuveen, LLC | 239,477 | +216,998 |
| American Century Companies Inc | 187,348 | -3,604 |
| Jacobs Levy Equity Management, Inc | 180,567 | -12,409 |
| Two Sigma Investments, LP | 165,514 | +20,884 |
| Morgan Stanley | 164,363 | +8,879 |
| D. E. Shaw & Co., Inc. | 156,835 | -25,648 |
| Allianz Asset Management GmbH | 142,399 | +24,900 |
| Bridgeway Capital Management, LLC | 138,153 | +39,060 |
Insiders
12 insiders reported holding 131,242 shares in total, about $1.8M at the last price.
| Holder | Shares |
|---|---|
| Guest KevinCEO & EXEC. CHAIRMAN OF BOARD | 45,381 |
| Nixon J ScottDirector | 13,077 |
| Wood Timothy EDirector | 13,061 |
| Winssinger Frederic JDirector | 11,365 |
| Ding XiaDirector | 9,306 |
| Noot WalterCHIEF OPERATING OFFICER | 9,256 |
| Mulham David MulhamCHIEF SALES OFFICER | 8,387 |
| Fleming John TurmanDirector | 7,494 |
| Pelosi PeggieDirector | 6,758 |
| Armstrong Kathryn MichelleCHIEF SCIENTIFIC OFFICER | 3,471 |
Questions about USNA
What does Usana Health Sciences Inc do?
Usana Health Sciences Inc is a company in the Health care sector, listed on NYSE as USNA. Its shares trade on NYSE under the ticker USNA.
What is Usana Health Sciences Inc's net worth?
Usana Health Sciences Inc has a market value (market cap) of $255.9M at the latest share price, and shareholders' equity of $526.3M on its balance sheet at July 4, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Usana Health Sciences Inc profitable?
No. Over the twelve months to July 4, 2026 it reported a net loss of $22.2M on revenue of $913.4M.
How much revenue does Usana Health Sciences Inc make?
Over the twelve months to July 4, 2026 Usana Health Sciences Inc reported revenue of $913.4M. That is 1.6% more than a year earlier.
When did Usana Health Sciences Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to July 4, 2026. Its newest filing of any kind is the quarterly results from November 3, 2026.
When is Usana Health Sciences Inc's next earnings report?
Usana Health Sciences Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare USNA with
Follow USNA
Get an email when Usana Health Sciences Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Usana Health Sciences Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.